Stay updated on Eli Lilly and Company Press Releases

Sign up to get notified when there's something new on the Eli Lilly and Company Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Eli Lilly and Company Press Releases page

  1. Check
    6 days ago
    Change Detected
    Summary
    New press releases have been added, including Lilly to acquire Centessa Pharmaceuticals and recent trial results (Taltz+Zepbound and EBGLYSS). Older releases (e.g., the orforglipron Lancet study) have been removed.
    Difference
    8%
    Check dated 2026-03-31T16:40:24.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Footer and legal/navigation links were added to the press releases page, including cookie settings, privacy policy, terms of use, sitemap, accessibility, and contact information.
    Difference
    100%
    Check dated 2026-03-24T10:53:10.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The new screenshot shows a blank page where the press releases listing should be; the old screenshot displayed the press releases and related navigation.
    Difference
    28%
    Check dated 2026-03-17T04:44:27.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    New entries for 03/09/2026 (CMMI BALANCE Model update) and 03/05/2026 (Lilly Employer Connect platform) were added, and two older items (Orna Therapeutics acquisition and 2025 Q4 results) were removed from the press releases list.
    Difference
    8%
    Check dated 2026-03-10T02:31:50.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Adds two new press releases on Olumiant and orforglipron; removes the Pennsylvania manufacturing facility announcement and the HRSA 340B response from the page.
    Difference
    9%
    Check dated 2026-03-02T21:33:33.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Added three press releases: Zepbound pricing and KwikPen availability; Omvoh Crohn's disease data; and TOGETHER-PsO efficacy data for Taltz and Zepbound. Removed three older items including the Q4 2025 results date, Breakthrough Therapy designation for sofetabart mipitecan, and the NVIDIA–Lilly AI Lab announcement.
    Difference
    8%
    Check dated 2026-02-23T17:49:41.000Z thumbnail image

Stay in the know with updates to Eli Lilly and Company Press Releases

Enter your email address, and we'll notify you when there's something new on the Eli Lilly and Company Press Releases page.